ABBV
AbbVie Inc.
NYSE · Healthcare · Drug Manufacturers - General · US
$256.34
−1.49%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 64.4B | 61.2B | 56.3B | 54.3B | 58.1B |
| Cost of Revenue | 18.4B | 18.2B | 16.9B | 20.4B | 17.4B |
| Gross Profit | 46.0B | 43.0B | 39.4B | 33.9B | 40.6B |
| Operating Expenses | |||||
| R&D Expense | 9.7B | 9.1B | 12.8B | 7.7B | 6.5B |
| SG&A Expense | 14.7B | 14.0B | 14.8B | 12.9B | 15.3B |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 2.8B | (241.0M) | 2.8B | 599.0M | 753.0M |
| Total Operating Expenses | 27.1B | 22.9B | 30.3B | 21.1B | 22.5B |
| Cost and Expenses | 45.5B | 41.1B | 47.2B | 41.6B | 39.9B |
| Operating Income (EBIT) | 18.9B | 20.1B | 9.1B | 12.8B | 18.1B |
| Non-Operating | |||||
| Interest Income | 270.0M | 266.0M | 648.0M | 540.0M | 186.0M |
| Interest Expense | 2.9B | 2.9B | 2.8B | 2.2B | 2.2B |
| Net Interest Income | (2.6B) | (2.6B) | (2.2B) | (1.7B) | (2.0B) |
| Other Non-Op Income/Expense | (10.2B) | (13.5B) | (5.4B) | (6.5B) | (4.6B) |
| Non-Operating Income (excl Interest) | 5.6B | 10.6B | 2.6B | 4.3B | 2.4B |
| EBT (Pre-Tax Income) | 8.7B | 6.6B | 3.7B | 6.3B | 13.5B |
| Income Tax Expense | 2.4B | 2.4B | (570.0M) | 1.4B | 1.6B |
| Bottom Line | |||||
| Net Income | 6.3B | 4.2B | 4.3B | 4.9B | 11.8B |
| Earnings from Cont. Ops | 6.3B | 4.2B | 4.3B | 4.9B | 11.8B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 6.3B | 4.2B | 4.2B | 4.8B | 11.8B |
| Per Share | |||||
| Basic EPS | $3.55 | $2.37 | $2.40 | $2.73 | $6.65 |
| Diluted EPS | $3.55 | $2.37 | $2.39 | $2.72 | $6.63 |
| Revenue Per Share | $36.36 | $34.48 | $31.85 | $30.72 | $32.78 |
| Shares | |||||
| Basic Shares Outstanding | 1.8B | 1.8B | 1.8B | 1.8B | 1.8B |
| Diluted Shares Outstanding | 1.8B | 1.8B | 1.8B | 1.8B | 1.8B |
| Profitability Metrics | |||||
| EBITDA | 21.2B | 17.6B | 14.9B | 17.2B | 24.2B |
| D&A | 7.9B | 8.1B | 8.4B | 8.7B | 8.5B |
| EBIT | 13.3B | 9.5B | 6.5B | 8.5B | 15.7B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026